Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PTGXVery BullishResearch Analysisnews

High materiality9/10

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?

Mar 10, 2025, 10:26 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive clinical trial results tend to correlate with stock price increases. For instance, successful trials for similar biotech firms have previously led to significant stock gains.

AI summary

What happened, with direct paths to the underlying reporting

PTGX reported positive Phase 2b results for icotrokinra in ulcerative colitis. Icotrokinra showed 63.5% response rate, significantly higher than placebo. Clinical remission rates improved at Week 12 for icotrokinra compared to placebo. Positive Phase 3 data for icotrokinra in psoriasis further boost potential. PTGX stock increased by 35.9% following the announcement.

PTGX reported positive Phase 2b results for icotrokinra in ulcerative colitis.
Icotrokinra showed 63.5% response rate, significantly higher than placebo.
Clinical remission rates improved at Week 12 for icotrokinra compared to placebo.
Positive Phase 3 data for icotrokinra in psoriasis further boost potential.
PTGX stock increased by 35.9% following the announcement.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.